Lawrence’s NxStage Medical Inc. jumped after the dialysis products manufacturer’s preliminary fourth-quarter sales numbers beat its own and analysts’ expectations. NxStage said it expects revenue of about $69 million, above its earlier guidance of between $67 and $68.5 million. The Street estimated $67.8 million. “ . . . we continue to target 15 percent annual revenue growth in the home in 2014,” CEO Jeffrey Burbank said in a statement. For the full year 2013, NxStage expects revenue of $263 million, above estimates.